Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
New Delhi [India], May 11: Dr.Harvansh Chawla, a distinguished legal expert and leader in international trade…
Sikkim [India], May 11: A new academic season is set to begin at MIT University Sikkim,…
Bengaluru (Karnataka) [India], May 11: Kennametal India Limited (KIL) reported revenues of ₹4031 million for…
Mumbai (Maharashtra) [India], May 8: The teaser of the much-awaited Hindi film Krishna Aur Chitthi…
Mumbai (Maharashtra) [India], May 9: A special book discussion and intellectual seminar on “Shatayu Sangh…
Mumbai (Maharashtra) [India], May 11: The film is produced by Nitin Narayanji Bhanushali and Vaishali…